MedTrace Logo

Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia

NCT04723901 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-01-26

No results posted yet for this study

Summary

Prospectively evaluate the safety and effectiveness of CD19/CD22 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Conditions

  • Dual-target CAR-T Cells
  • B ALL
  • Relapse
  • Refractory B Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

Dual target CAR-T cell therapy

CD19/CD22 dual target CAR-T cell therapy

Sponsors & Collaborators

  • Shenzhen University General Hospital

    lead OTHER

Principal Investigators

  • Li Yu, Dr · Shenzhen University General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04723901 on ClinicalTrials.gov